Shock wave lithotripsy to the penis is also an idea that is sometimes marketed but has been shown to be ineffective
[DOI] [PubMed] [Google Scholar] 22.Conover CA, Baker BK, Bale LK, Clarkson JT, Liu F, Hintz RL
Injectable weight loss drugs known as GLP-1s have become enormously popular over the last few years
Tesofensine May Be Better For: Patients who strongly prefer oral medication over injections Individuals whose eating patterns are driven primarily by cravings, emotional eating, or reward-seeking behavior (dopamine-mediated eating) Patients who have not responded adequately to GLP-1 medications Those who tolerate stimulant-type medications well Individuals without significant cardiovascular risk factors Semaglutide May Be Better For: Patients with type 2 diabetes or prediabetes (dual benefit of weight loss and glycemic control) Individuals with cardiovascular disease or elevated cardiovascular risk (proven cardioprotective benefit) Patients who prefer weekly dosing over daily medication Those who experience primarily volume-driven overeating rather than craving-driven eating Individuals with a history of anxiety or insomnia (since semaglutide does not have stimulant properties) Combination Therapy Some physicians prescribe tesofensine and semaglutide together, leveraging their complementary mechanisms tesofensine addressing central nervous system-mediated cravings while semaglutide handles peripheral satiety and metabolic improvements
2 Ask your prescriber about Bridge eligibility If you are a Medicare beneficiary seeking Wegovy for weight loss, ask your provider whether you meet Bridge criteria (BMI 35+, or 30+ with qualifying comorbidities, or 27+ with prediabetes or prior CV event) and whether you are currently on a Part D-covered GLP-1 (which would make you ineligible)
For example, tariffs on raw materials or export restrictions in key manufacturing countries could increase costs or limit access to critical ingredients
